Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin lingual spray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. 4.1 pde-5-inhibitors and sgc-stimulators do not use nitroglycerin lingual spray in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitroglycerin lingual spray in patients who are taking the soluble guanylate cyclase (sgc) stimulator riociguat. concomitant use can cause hypotension. 4.2 severe anemia nitroglycerin lingual spray is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 increased intracranial pressure nitroglycerin lingual spray may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e. g. cerebral

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin lingual spray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. 4.1 pde-5-inhibitors and sgc-stimulators do not use nitroglycerin lingual spray in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitroglycerin lingual spray in patients who are taking the soluble guanylate cyclase (sgc) stimulator riociguat. concomitant use can cause hypotension. 4.2 severe anemia nitroglycerin lingual spray is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 increased intracranial pressure nitroglycerin lingual spray may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e. g. cerebral

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f), olodaterol hydrochloride (unii: 65r445w3v9) (olodaterol - unii:vd2ysn1afd) - tiotropium 3.124 ug - stiolto respimat is a combination of tiotropium and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use - stiolto respimat is not indicated to treat acute deteriorations of copd [see warnings and precautions (5.2)]. - stiolto respimat is not indicated to treat asthma. the safety and effectiveness of stiolto respimat in asthma have not been established. use of a laba, including stiolto respimat, without an inhaled corticosteroid is contraindicated in patients with asthma [see warnings and precautions (5.1)] . stiolto respimat is not indicated for the treatment of asthma. stiolto respimat is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product [see warnings and precautions (5.4)] . in clinical trials and postmarketing experience with tiotropium, immediate hypersensitivity reactions, inc

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

aytu biopharma, inc. - zolpidem tartrate (unii: wy6w63843k) (zolpidem - unii:7k383oqi23) - zolpimist (zolpidem tartrate) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. zolpidem tartrate has been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see clinical studies ( 14)]. the clinical trials performed in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. zolpimist is contraindicated in patients: zolpimist is contraindicated in patients: - who have experienced complex sleep behaviors after taking zolpimist [see warnings and precautions ( 5.1)] [see warnings and precautions ( 5.1)] - with known hypersensitivity to zolpidem tartrate [ see warnings and precautions ( 5.7)]. pregnancy category c there are no adequate and well-controlled studies of zolpimist in pregnant women. studies in children to asse

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - olodaterol hydrochloride (unii: 65r445w3v9) (olodaterol - unii:vd2ysn1afd) - olodaterol 2.5 ug - striverdi respimat is a long-acting beta2 -agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. striverdi respimat is not indicated to treat acute deteriorations of copd [see warnings and precautions (5.2) ]. striverdi respimat is not indicated to treat asthma. the safety and effectiveness of striverdi respimat in asthma have not been established. use of a laba, including striverdi respimat, without an inhaled corticosteroid is contraindicated in patients with asthma [see warnings and precautions (5.1) ]. striverdi respimat is not indicated for the treatment of asthma. risk summary there are no adequate and well-controlled clinical studies with striverdi respimat in pregnant women to inform of drug-associated risk of adverse pregnancy-related outcomes. there are clinical considerations with the use of striverdi respimat in pregnant women [see clinica

Филипини - Енглески - FDA (Food And Drug Administration)

primemed co., inc - atorvastatin (as calcium) - tablet, film coated - 20mg

Филипини - Енглески - FDA (Food And Drug Administration)

primemed co., inc,. - clopidogrel (as bisulfate) - film-coated tablet - 75mg

Филипини - Енглески - FDA (Food And Drug Administration)

primemed co., inc. - esomeprazole - enteric-coated tablet - 75mg

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium bromide - unii:j697uz2a9j) - ipratropium bromide 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. atrovent hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to ipratropium bromide or other atrovent hfa inhalation aerosol components. atrovent hfa inhalation aerosol is also contraindicated in patients who are hypersensitive to atropine or its derivatives. atrovent® hfa (ipratropium bromide hfa) inhalation aerosol read complete instructions carefully before using. important points to remember about using atrovent hfa inhalation aerosol    although atrovent hfa inhalation aerosol may taste and feel different    when breathed in compared to your atrovent® (ipratropium    bromide) inhalation aerosol cfc inhaler, they contain the same    medicine.    you do not have to shake the atrovent hfa inhalation aerosol canister    before using it.    atrovent hfa inhala

Израел - Енглески - Ministry of Health

gilead sciences israel ltd - anti-cd19 car t cells - dispersion for infusion - anti-cd19 car t cells - acute lymphoblastic leukaemia tecartus is indicated for the treatment of adult patients with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).mantle cell lymphoma tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton's tyrosine kinase (btk) inhibitor unless ineligible to btk inhibitor •limitation of use : tecartus is not indicated for the treatment of patients with active central nervous system lymphoma